BACKGROUND: Morphologic and clinical heterogeneity within tumor grades is well recognized in prostate cancer. The objective of the current study was to determine whether the combined percentage of Gleason patterns 4 and 5 in radical prostatectomy specimens is an independent predictor of cancer-specific survival in prostate cancer patients. METHODS: The radical prostatectomy specimens were analyzed from 504 consecutive prostate cancer patients who were treated at Indiana University Medical Center between 1990 and 1998. Various clinical and pathologic characteristics were analyzed. RESULTS: A higher combined percentage of Gleason patterns 4 and 5 was associated with older age, higher preoperative serum prostate-specific antigen level, higher pathologic stage, positive surgical margins, extraprostatic extension of tumor, higher Gleason score, perineural invasion, and lymph node metastasis. In the multivariate Cox regression model, the combined percentage of Gleason patterns 4 and 5 was found to be an independent predictor of cancer-specific survival (P = .04). CONCLUSIONS: The combined percentage of Gleason patterns 4 and 5 is a powerful predictor of prostate cancer-specific survival. Assessment of high-grade cancer amounts may allow for better stratification of patients into appropriate prognostic groups and treatment protocols.
BACKGROUND: Morphologic and clinical heterogeneity within tumor grades is well recognized in prostate cancer. The objective of the current study was to determine whether the combined percentage of Gleason patterns 4 and 5 in radical prostatectomy specimens is an independent predictor of cancer-specific survival in prostate cancerpatients. METHODS: The radical prostatectomy specimens were analyzed from 504 consecutive prostate cancerpatients who were treated at Indiana University Medical Center between 1990 and 1998. Various clinical and pathologic characteristics were analyzed. RESULTS: A higher combined percentage of Gleason patterns 4 and 5 was associated with older age, higher preoperative serum prostate-specific antigen level, higher pathologic stage, positive surgical margins, extraprostatic extension of tumor, higher Gleason score, perineural invasion, and lymph node metastasis. In the multivariate Cox regression model, the combined percentage of Gleason patterns 4 and 5 was found to be an independent predictor of cancer-specific survival (P = .04). CONCLUSIONS: The combined percentage of Gleason patterns 4 and 5 is a powerful predictor of prostate cancer-specific survival. Assessment of high-grade cancer amounts may allow for better stratification of patients into appropriate prognostic groups and treatment protocols.
Authors: Andrew B Rosenkrantz; Michael J Triolo; Jonathan Melamed; Henry Rusinek; Samir S Taneja; Fang-Ming Deng Journal: J Magn Reson Imaging Date: 2014-02-25 Impact factor: 4.813
Authors: Kenneth A Iczkowski; Kathleen C Torkko; Gregory R Kotnis; R Storey Wilson; Wei Huang; Thomas M Wheeler; Andrea M Abeyta; Francisco G La Rosa; Shelly Cook; Priya N Werahera; M Scott Lucia Journal: Am J Clin Pathol Date: 2011-07 Impact factor: 2.493
Authors: Kristen L Zakian; Hedvig Hricak; Nicole Ishill; Victor E Reuter; Steven Eberhardt; Chaya S Moskowitz; Amita Shukla-Dave; Liang Wang; Peter T Scardino; James A Eastham; Jason A Koutcher Journal: J Urol Date: 2010-10-16 Impact factor: 7.450
Authors: Fang-Ming Deng; Nicholas M Donin; Ruth Pe Benito; Jonathan Melamed; Julien Le Nobin; Ming Zhou; Sisi Ma; Jinhua Wang; Herbert Lepor Journal: Eur Urol Date: 2015-10-30 Impact factor: 20.096
Authors: Yujiro Ito; Kazuma Udo; Emily A Vertosick; Daniel D Sjoberg; Andrew J Vickers; Hikmat A Al-Ahmadie; Ying-Bei Chen; Anuradha Gopalan; S Joseph Sirintrapun; Satish K Tickoo; Peter T Scardino; James A Eastham; Victor E Reuter; Samson W Fine Journal: J Urol Date: 2019-03 Impact factor: 7.450
Authors: Mario A Eisenberger; Tamara L Lotan; Pedro Isaacsson Velho; David Lim; Hao Wang; Jong Chul Park; Harsimar B Kaur; Fawaz Almutairi; Michael A Carducci; Samuel R Denmeade; Mark C Markowski; William B Isaacs; Emmanuel S Antonarakis; Colin C Pritchard Journal: JCO Precis Oncol Date: 2019-07-26